Population pharmacokinetic model for prevention of magnesium sulfate toxicity in pregnant women with pre-eclampsia
pharmacokinetics, preeclampsia, magnesium sulfate, toxicity.
Magnesium sulfate is the treatment of choice for the prevention or control of seizures associated with pre-eclampsia. However, the occurrence of adverse reactions to magnesium sulfate is elevated. The aim of study is develop a population pharmacokinetic model considering individual patient characteristics aimed at an improved dose definition for the prevention of toxicity in pregnant women with pre-eclampsia (PE). Prospective cohort of patients with preeclampsia administered magnesium sulfate. The patients (n = 111) received 4 g of magnesium sulphate intravenously followed by the hourly infusion of 1 g during 24 hours. Serum magnesium levels were measured in blood samples obtained before administration and 2, 6, 12 and 18 hours after the initial dose and 4 h after the end of the administration. Adverse reactions to magnesium sulphate were investigated through active search. Population pharmacokinetic parameters were estimated using the Monolix software® 2018 Suite (Lixoft®, Antony, France). Demographic, clinical and laboratory variables were tested for significance. A 1-compartment model was adopted. Patients with a lower body weight and higher serum creatinine are more susceptible to magnesium toxicity. The population pharmacokinetics model proposes the adoption of individualized dosing schemes of magnesium sulfate based on creatinine and body weight in order to prevent toxicity manifestations.